| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | SGX-523 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | erismodegib | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.0079 | 0.9 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.0076 | 0.9 |